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Abstract: Gut microbial composition alters in some special situations, such as in ulcerative colits
(UC) after total proctocolectomy and ileal pouch-anal anastomosis (IPAA) surgery. The aim of our
study was to determine the composition of the intestinal microbiome in UC patients after IPAA
surgery, compared with UC patients, familial adenomatous polyposis (FAP) patients after IPAA
surgery and healthy controls. Clinical data of patients, blood and faecal samples were collected.
Faecal microbiota structure was determined by sequencing the V4 hypervariable region of the
16S rRNA gene. Overall, 56 patients were enrolled. Compared to the Healthy group, both the
Pouch active and UC active groups had higher Enterobacteriaceae, Enterococcaceae and Pasteurellaceae
abundance. The Pouch and UC groups showed distinct separation based on their alpha and beta
bacterial diversities. The UC group had higher Prevotellaceae, Rikenellaceae, Ruminococcaceae abundance
compared to the Pouch active group. Pouch and FAP participants showed similar bacterial community
composition. There was no significant difference in the bacterial abundance between the active and
inactive subgroups of the Pouch or UC groups. Gut microbiome and anatomical status together
construct a functional unit that has influence on diversity, in addition to intestinal inflammation that
is a part of the pathomechanism in UC.
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1. Introduction
The gut microbiome has a great role in some physiological processes in the human body, such as
the biosynthesis of vitamins and amino acids, breaking down food compounds, resistance of pathogens,
protection against epithelial injury, development and training of immune system, but also to promote
angiogenesis, fat storage and modify nervous and immune actions. Not only physiological, but its
pathological role is more and more obvious based on human microbiota studies, as well. Most of studies
focus on bacterial microbiota composition as a component of the gut microbiota. It contains more than
1000 bacterial species and 100-fold more genes than are found in the human genome [1]. In the healthy
gut, most of the bacteria belong to Firmicutes, Bacteroidetes, Actinobacteria and Verrucomicrobia [2], and an
imbalance of these phyla can drive to dysbiosis. Gut dysbiosis is associated with inflammatory bowel
diseases (IBD); ulcerative colitis (UC), Crohn’s disease (CD) including reduced diversity of bacteria,
decreased abundance of Firmicutes, Bacteroides and increased abundance of Gammaproteobacteria [1].
Enterobacteriaceae was present in high abundance in clinical and animal-mice-studies [3]. As a member
of that family, Escherichia coli, especially adherent-invasive E.coli, were isolated from biopsies of ileal
CD and UC patients [1]. Nevertheless, we can mention other species that were suggested by previous
studies as being associated with IBD, such as the adherent and invasive Fusobacteria, which mostly
colonises the oral cavity and the gut, and it has been shown that it has a higher abundance in active
IBD, particularly in colon of UC patients compared to healthy population [1,4]. The The short-chain
fatty acids (SCFAs)-producing Roseburia is another bacteria that is depleted in IBD [1].
The microbiome shows differences in terms of proximal to distal gut1. Some special changes
have also been reported with regard to the type and localisation of IBD. Microbial composition alters
in some special situations like in UC after total proctocolectomy and ileal pouch-anal anastomosis
(IPAA) surgery. Inflammation of the pouch, i.e., pouchitis, is the most frequent complication after
UC surgery. It occurs in approx. half of the operated patients; moreover, some data suggest that 40%
of pouchitis develops within 12 months after surgery [5]. Some studies have suggested that risk for
pouchitis after colectomy in UC can be predicted by microbiota composition [6,7]. The connection
between dysbiosis and the development of inflammation in UC patients with pouch is not completely
understood. The data of inflammation course and dysbiosis after proctocolectomy and IPAA surgery
in UC are insufficient to determine the cause and consequence relationship. Some medications, such as
anti-inflammatory drug mesalamine, could diminish mucosal inflammation in parallel with decreasing
the abundance of Escherichia and/or Shigella [1]. Data from longitudinal analysis of the IBD microbiome
demonstrate that the course of corticosteroids had an influence on microbiome fluctuation compared
to bacterial composition of samples from patients who were on a stable dose of medication [8].
However, metronidazole and ciprofloxacin antibiotic course is effective and recommended in majority
of pouchitis cases, contrary to UC with an intact colon where data are conflicting and insufficient
to verify effectiveness for the maintenance of remission in UC, only if infection is considered [9].
Despite this, familial adenomatous polyposis syndrome (FAP) is a disease with different aetiology,
course and outcome, which may require the same surgical procedure as refractory UC. However,
pouchitis is uncommon among FAP patients who underwent IPAA formation. Based on the above,
we constructed a clinical model of two separate bowel diseases with identical anatomical structure.
Our aim was to determine whether alteration in bacterial abundance correlates with the type of disease
(UC vs. FAP) and localisation of disease (UC with vs. without pouch). We hypothesised that anatomical
variance (i.e., pouch) is associated with the effect that bacterial alterations have on the gut microbiota.
Functional anatomical changes may explain differences in the effectiveness of the treatment of intact
UC and UC patients with pouch.
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2. Results
2.1. Demographics and Clinical Data
Overall, 56 participants were enrolled in this prospective, observational, single-centre study: 22 UC
patients with a pouch (abbreviated as Pouch (P)), 15 UC patients without a pouch (abbreviated as UC),
6 FAP patients with a pouch (abbreviated as FAP (F)) and 13 healthy volunteers (abbreviated as Healthy
(H)). Pouch and UC categories were divided into active (A) and inactive (I) subcategories depending on
the inflammatory state of the disease (see definition in the Method section). Samples were obtained from
participants who have not been exposed to antibiotics or probiotics for at least 6 weeks prior to study
enrolment (see inclusion and exclusion criteria in the Methods and Definitions sections). Demographic
and clinical data were comparable between active and inactive Pouch patients. The mean pouch age
(time after ileostomy closure) was 5 (SD: 4.6) years. Participants in this study were mostly middle-aged
(mean age 45 [SD: 13.9] years). Screening microbiology stool tests excluded the most relevant infectious
diseases (e.g., Clostridium difficile, Salmonella) in every enrolled participant. Most of the UC patients
without a pouch had left sided or extensive colitis (based on Montreal classification UC distribution
was as follows: The E1 type had 2, E2 type had 7 and E3 type had 6 patients). About two-thirds of the
Pouch patients had a “mature pouch”, i.e., the time of ileostomy closure was more than 5 years (mature
pouch, 63.6%, immature pouch, 36.4%). At the same time, four out of the nine with pouchitis and 10 out
of the 13 without pouchitis patients had a mature pouch. Patients were on a stable dose of medication,
as detailed in Table 1, with other demographic data. Since antibiotics have a great significance in
pouchitis treatment, we analysed the proportion of antibiotic use and its effectiveness, and found that
14 out of 22 Pouch patients (63.6%) had ever received antibiotic therapy due to pouchitis. Eighty-four
point five percent of these Pouch patients were antibiotic responders—in other words, they achieved
remission after an antibiotic course without need of any immunosuppressant or anti-inflammatory
drugs. Regarding serum laboratory parameters, these reflected degree of inflammation (Table 1).
The mean levels of inflammatory biomarkers such as serum CRP and faecal calprotectin were higher in
active disease, but did not correlate with bacterial composition. Between-group ANOVA on ranks
analysis demonstrated significant differences in calprotectin levels (p < 0.001), and further testing
showed higher calprotectin in Pouch active patients than in Pouch inactive patients (p = 0.008) or FAP
patients (p = 0.008), but not between FAP and Pouch inactive patients (p = 0.2).
2.2. Bacterial Diversity of the Examined Groups
We examined differences in bacterial profiles between samples of investigated groups with the
Wilcoxon rank sum test and found significant separation by diagnosis (Figures 1 and 2). Bacterial families
(and OTU categories also) with the greatest changes in alpha diversity differed markedly between
Pouch and healthy (p < 0.001), UC without pouch and healthy (p = 0.002), and FAP and healthy
(p = 0.0005) (Figure 3). We found decreased alpha diversity in both Pouch and FAP samples compared
to UC patients without a pouch (p < 0.001 and p = 0.02). The healthy group was characterised by the
greatest alpha diversity, then decreased variety was observed in UC patients without a pouch, and the
lowest diversity was found in Pouch and FAP patients. This separation is presented by beta diversity,
as well (Figure 2). Paired permutational multivariate analysis of variance confirm differences between
all groups by beta diversity, except between Pouch and FAP groups, which were similar (p = 0.09 for
FAP vs. Pouch active, p = 0.501 for FAP vs. Pouch inactive).
Pharmaceuticals 2020, 13, 346 4 of 16
Table 1. Patients’ demographic, clinical and biochemical features.
Ulcerative colitis (UC) UC-Pouch (P) FAP (F) Healthy (H)
Active Inactive Total Active Inactive Total
No. of patients 7 8 15 9 13 22 6 13
Gender (male/female), No. of patients 6/1 5/3 11/4 4/5 8/5 12/10 3/3 6/7
age at inclusion (SD, years) 48.6 (21.7) 45.1 (14.6) 46.7 (17.6) 51.5 (13.9) 41.3 (12.8) 45(13.9) 31.7 (6.5) 32.35 (7.45)
disease duration at inclusion (SD, years) 10.9 (11.1) 11.4 (9) 11.1 (9.6) 14 (6.7) 15.1 (10.5) 15 (9) 11.9 (7.3) NA
time after IPAA surgery (SD, years) NA NA NA 4.6 (4.2) 5 (5) 5 (4.6) 8.7 (7.4) NA
Therapy (No. of patients)
none 1 0 1 2 9 11 6 13
oral 5-ASA 3 6 9 0 0 0 0 0
topical 5-ASA 1 3 4 2 0 2 0 0
oral corticosteroid 3 2 5 1 0 1 0 0
topical corticosteroid 2 2 4 0 0 0 0 0
azathioprine 2 4 6 0 0 0 0 0
biological therapy (IFX, ADA) 1 0 1 0 0 0 0 0
Laboratory parameters
faecalcalprotectin (median, min–max, µg/g) 1000(116.4–1000)
303.4
(12.6–1000)
360.2
(12.6–1000)
1000
(38.8–1800)
428
(100–1222)
691.7
(38.8–1800)
284.8
(145.1–711.7) 11.8 (6.9–20.5)
CRP (mean, SD, mg/L) 17.8 (17.5) 7.7 (5.1) 12.7 (13.5) 9.3 (5.1) 7.3 (4.6) 7.8 (4.6) 2.1 (0.2) NA
serum iron (mean, SD, µmol/L) 10.9 (7.3) 16.6 (5.7) 13.7 (7) 9.1 (8.5) 12 (6.8) 11 (7.3) NA NA
haematocrit (mean, SD, L/L) 39 (5.5) 42.3 (5) 40.6 (5.3) 38 (4.4) 42.9 (3.5) 41(4.5) 42 (3.3) NA
thrombocytes (mean, SD, G/L) 335.4 (93.4) 262 (51.4) 298.7 (81.9) 349 (121.1) 291.3 (73.5) 315.6 (97.8) 309.5(162.7) NA
albumin (mean, SD, g/L) 42.4 (5.3) 47.3 (3.7) 44.9 (5.1) 42 (6.9) 46.8 (2.9) 45.3 (4.8) 41.5 (2.1) NA
NA—not applicable; IPAA—ileal pouch-anal anastomosis; 5-ASA-5-aminosalycilic acid.
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Figure 1. Alpha diversities of the main groups. Data represent Fisher alpha diversity indices at the
OTU level based on 16S rRNA profiling of the V4 region. *** indicates significant differences from
two-sided Wilcoxon rank sum test p = 3.4 × 10−6, 0.0008 and 4.4 × 10−5 for Healthy versus Pouch,
Healthy versus FAP, and Pouch versus UC groups, respectively; ** indicates significant differences from
two-sided Wilcoxon rank sum test, p = 0.0053 for Healthy versus UC groups; * indicates significant
difference from two-sided Wilcoxon rank sum test, p = 0.0195 for UC versus FAP groups; sample sizes
were 6, 13, 22 and 15 for FAP, Healthy, Pouch and UC groups, respectively. Central horizontal bars
represent median values. For details, see Table S2.
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Microbiome profiles of UC with and without pouch patients were associated with numerous
dysbiosis-associated families, including low abundance of the butyrate producing Acidaminococcaceae,
Bacteriodeaceae, Porphyromonodaceae, Prevotellaceae, Rikenellaceae, Ruminococcaceae and high
abundance of Clostridiaceae, Enterobacteriaceae and Enterococcaceae. Features, with major differences
including a decreased abundance of Bacteroidetes phylum, which was largely specific for both UC
with and without a pouch. In contrast, the abundance of Gammaproteobacteria was higher in both
UC groups than in healthy participants; moreover, it was the highest in both the UC and FAP with
a pouch groups. Interestingly, we did not find significant associations of pouchitis with bacterial
diversity. Furthermore, focusing on the shift of bacterial families, some taxa were identified by Wilcox
test to be less or more abundant in compared groups (Table 2). In samples of Pouch, sequence
analysis of bacterial families revealed that Desulfovibrionaceae, Rikenellaceae, Ruminococcaceae were
less abundant, and Clostridiaceae, Enterobacteriaceae, Pasteurellaceae, Peptostreptococcaceae and
Streptococcaceae were more abundant compared to healthy controls. Although Verrucomicrobiaceae,
Rikenellaceae and Ruminococcaceae were more abundant in UC patients without pouch compared
to Pouch patients. In both types of IBD samples, Pasteurellaceae showed higher abundance than
in healthy samples. Pouch and FAP participants showed similar bacterial community composition,
and there was no significant difference in any bacterial family abundance between groups.
Accordingly, during maturation of the pouch, some structural and functional changes develop,
and thus there may be some alterations in local microbiota as well. Even so, we did not find any major
differences in beta diversity between mature and immature pouches (Figure 4).
Table 2. Differences in bacterial family abundance between compared groups. Some taxa were identify
to less or more abundant in compared groups. Only significant shifts are presented.
Compared Groups Higher or Lower Abundance Group Taxonomic Annotation Adjusted p Value
Healthy vs. Pouch active
less abundant in Pouch active
Acidaminococcaceae 0.032
Porphyromonadaceae 0.007
Prevotellaceae <0.001
Rikenellaceae <0.001
Ruminococcaceae 0.007
more abundant in Pouch active
Actinomycetaceae 0.040
Clostridiaceae 0.016
Enterobacteriaceae <0.001
Enterococcaceae 0.011
Pasteurellaceae 0.007
Streptococcaceae <0.001
Healthy vs. Pouch inactive
less abundant in Pouch inactive
Bacteroidaceae 0.018
Desulfovibrionaceae 0.018
Porphyromonadaceae 0.018
Rikenellaceae 0.002
Ruminococcaceae 0.037
more abundant in Pouch inactive
Clostridiaceae 0.018
Enterobacteriaceae <0.001
Pasteurellaceae 0.018
Peptostreptococcaceae 0.004
Streptococcaceae 0.018
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Table 2. Cont.
Compared Groups Higher or Lower Abundance Group Taxonomic Annotation Adjusted p Value
Pouch active vs. UC inactive
less abundant in UC inactive Clostridiaceae_1 0.04
more abundant in UC inactive
Acidaminococcaceae 0.01
Porphyromonadaceae <0.001
Prevotellaceae <0.001
Rikenellaceae <0.001
Ruminococcaceae <0.001
Pouch active vs. UC active more abundant in UC active
Prevotellaceae 0.015
Rikenellaceae 0.020
Ruminococcaceae 0.015
Verrucomicrobiaceae 0.015
Pouch inactive vs. UC active more abundant in UC active Verrucomicrobiaceae 0.031
Pouch inactive vs. UC inactive less abundant in UC inactive Peptostreptococcaceae 0.029
Healthy vs. UC active more abundant in UC active
Pasteurellaceae 0.011
Enterobacteriaceae <0.001
Enterococcaceae 0.041
Healthy vs. UC inactive more abundant in UC inactive Pasteurellaceae 0.042
Bacillales_Incertae_Sedis_XI 0.039
Enterobacteriaceae <0.001
Micrococcaceae 0.049
Pasteurellaceae <0.001
Peptostreptococcaceae 0.001
Streptococcaceae 0.001
more abundant in healthy
Acidaminococcaceae 0.004
Porphyromonadaceae 0.002
FAP vs. UC inactive
less abundant in UC inactive Peptostreptococcaceae 0.019
more abundant in UC inactive
Porphyromonadaceae 0.009
Rikenellaceae 0.040
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3. Discussion
We found that bacterial diversity of healthy controls and subtypes of UC formed distinct bunches;
moreover, the non-IBD colectomised group was closer to colectomised UC patients than healthy controls
by principal coordinates analysis of unweighted Unifrac distances. As suggested in previous studies,
large differences were found in alpha and beta diversity between healthy and UC patients. Shifts in
participants with UC mirrored earlier observations of dysbiosis, relative reduction in Acidaminococcaceae,
Bacteriodeaceae, Porphyromonodaceae, Prevotellaceae, Rikenellaceae, Ruminococcaceae, and higher abundance
of Clostridiaceae, Enterobacteriaceae and Enterococcaceae. These observations are consistent with the
results of a study [10] which recruited 140 pouch patients that show that bacterial diversity in UC
patients is lower than in healthy subjects. Reshef et al. in this study [10] noticed little difference in
microbiota composition between UC with non-pouchitis, UC with pouchitis and FAP with pouch
samples. They did not find diversity difference between samples of UC with non-pouchitis, FAP with
pouch and UC without pouch. However, it should be noted that in further analysis, they discovered a
reduction in Faecalibacterium in patients with UC pouchitis compared to UC non-pouchitis and FAP
pouch participants [10]. Li et al. found less diverse microbiota in patients with UC and UC with
pouch compared to healthy samples, and likewise in our study, patients with a pouch had an altered
microbiota composition compared with UC patients [11].
Halfvarson et al. calculated the mean distance of taxa from each observed IBD sample to the
healthy plane and revealed that all subtypes of IBD significantly deviated from healthy samples [8].
The colonic CD and UC samples were closer to the healthy plane than ileal CD samples and the highest
volatility was observed for ileal CD patients who had underwent ileocoecal resection. The authors
explained that the high volatility was due to the removal of the ileocoecal valve and altered intestinal
physiology. Their results suggest the importance of disease localisation/extension, whether is it colonic
or ileal or resected gut. In our study, Pouch and FAP samples showed high similarity linked to
bacterial diversities. On the other hand, both Pouch and FAP samples significantly differed from
healthy and UC without pouch samples, as well. Shifts in colectomised participants, both with UC
or FAP, showed similar differences, namely, depletion of Bacteroidetes and enrichment of Firmicutes
and Proteobacteria. We think that differences were largely driven by altered anatomical conditions as a
result of surgery. Moreover, based on our results, it seems that anatomical status may be as significant
as disease type itself or the presence of pouchitis. However, some data from previous prospective
studies demonstrate that UC patients with a pouch had diminished diversity compared to FAP patients
with pouch [5,12]. We identify some bacterial families specific for UC and colectomised participants
that verify dysbiotic environmental of gut. Microbiome varies along the human gastrointestinal (GI)
tract, which justifies the study by Vasapolli et al. where the predominant genera in the upper GI tract
(Gemella, Veillonella, Neisseria, Fusobacterium, Streptococcus, Prevotella, Pseudomonas and Actinomyces)
were almost absent from the lower GI tract, where the microbial communities mainly comprised
Faecalibacterium, Ruminococcus, and Bacteroides [13]. Another example for the importance of localisation
is that more and more data are available about intestinal microbiome divergence between ileal and
colon CD [4,8,14]. Naftali et al. suggested different underlying mechanism due to the highly significant
separation of the microbiome of ileal and colon CD samples which was unaffected by the biopsy’s
location, inflammatory state or patient’s condition (i.e., remission or relapse) [4]. They observed higher
microbial dysbiosis index values in ileal samples compared to colon, meaning more severe dysbiosis in
those patients. A study group from Israel published their gene expression-investigation findings about
no alteration in gene expression in UC patients with normal ileal mucosa; however, IPAA surgical
intervention was associated with some molecular changes. Interestingly, these changes were observed
in patients with FAP who underwent IPAA surgery. It should be added that more significant gene
expression changes were among UC patients with a pouch than in FAP patients with a pouch. In this
study, UC, non-pouchitis UC, pouchitis UC and Crohn’s disease-like pouchitis showed a spectrum of
molecular changes associated with disease phenotypes and the severity of inflammation [15].
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Studies suggest that some bacterial species predict pouchitis [16] even before total colectomy
and IPAA formation and thus this may be an opportunity to express an outcome [5]. A study from
Leuven indicated that the predominant presence of Ruminococcus gnavus, Bacteroides vulgatus and
Clostridium perfringens and absence of Blautia spp and Roseburia spp in faecal samples of patients
with UC before colectomy increased the risk of pouchitis [6]. In another work, the authors found an
association between pouchitis and decreased Ruminococcus, Lachnospira and Coprococcus genera [17].
A number of studies showed the difference by diversity between pouchitis and non-pouchitis
patients supporting the association between inflammation and dysbiosis. As an element of dysbiosis,
reduction in Ruminococcaceae was noticed in our investigation, as well. Lactobacillus, Bifidobacterium and
Faecalibacterium have been shown to be protective by the stimulation of anti-inflammatory cytokine
production and down-regulation of inflammatory cytokines [1]. Faecalibacterium prauznitzii was
underrepresented in specimens of IBD patients; moreover, some studies reported lower abundance in
ileal CD than in colon CD samples [4] and higher rates of relapse of post-surgery CD [1]; restitution of
F.prauznitzii and maintenance of remission in UC showed connection [1]. The reason for this could be
that the Faecalibacterium genus belongs to Ruminococcaceae, which has a role in butyrate production.
The short-chain fatty acids’ (SCFAs) beneficial effects (such as being the primary energy source of
colonic epithelial cells) on the intestinal mucosa have been verified [1]. Some studies confirmed no
significant differences between the bacterial cultures of pouchitis and non-pouchitis patients [18,19].
However, not all papers have been able to verify these findings [20], demonstrating the complexity of
the topic.
In general, Firmicutes and Bacteroidetes play an important role in influencing dysbiosis that could
be associated with the modulation of immune response; however, evidence is conflicting. We verified
the lower abundance of Bacteroidetes and higher abundance of Firmicutes and Proteobacteria in Pouch
patients when compared to heathy participants. In addition, Bacteroidetes were more decreased related
to active UC pouch patients than in inactive UC patients, which suggests an association between low
abundance of Bacteroidetes and inflammation; in the same way, Bacteroidetes had lower abundance also
in FAP patients compared to inactive UC patients, which represents a connection with gut structural
modification, i.e., decreased host carrying capacity besides IBD or abnormal immune response-related
microbial alterations. Clostridium and Bacteroides species could facilitate the expansion of T reg cells
that attenuate intestinal inflammation [1]. F. prauznitzii, Clostridia and B.fragilis could mitigate the
severity of colitis in some mice models [1]. Besides that, data from other studies analogous with our
results confirmed only limited differences between pouchitis and non-pouchitis in a matter of bacterial
composition [21]. A previous study suggested a relative increase in Proteobacteria—more precisely,
Proteobacteria are able to sustain a constant density in the individuals with IBD, while the remaining
phyla decrease in density [22]. Corresponding to the literature, the abundance of Proteobacteria was
higher in both active and inactive UC patients compared to healthy controls in our study. Nevertheless,
Proteobacteria is the typical phylum that exists in the small intestine where transit is faster than in the
colon, and simple sugar and amino acid metabolism is favoured, thus rapidly dividing facultative
anaerobe communities dominate; whereas the slow flow colon, where metabolism is dominated by
the fermentation of complex polysaccharides, results in a great diversity of species (e.g., Bacteroidales,
Clostridiales) [23]. In accordance with that knowledge, in our study, Proteobacteria was more abundant
in both Pouch and FAP patients, and we found more Bacteroidales in UC samples than in samples of
colectomised patients.
If associations exist between low bacterial diversity and inflammation, thus it would be logical
to be a relationship between low bacterial diversity and elevated inflammatory markers. Similarly
to our result, Halfvarson et al. [8] observed higher faecal calprotectin concentrations in IBD patients
compared to healthy controls; however, they did not found correlation between faecal calprotectin
and distance from the healthy plane, as we did not detect any connection between calprotectin and
bacterial diversities.
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We need to take into account that the mechanism of gut dysbiosis related to IBD is not only driven
by inflammation-associated microbiota alterations, because this view is challenged by data which
proved that dysbiosis exists in patients with remission. Microbiota density is influenced by both the
host’s carrying capacity and the fitness of the microbiota. Carrying capacity—that is, the maximal
density of organisms supported by an ecosystem—depends on environmental resources and the ability
to effectively utilise the available sources [22]. Significantly decreased microbiota diversity suggests
that an altered gut structure (total proctocolectomy and IPAA formation) has a large influence on
carrying capacity. Some data suggest that the microbiome composition of the pouch changes over
the time (shifts from “ileal to colonic type”) [7,24,25]. Nonetheless, diversity differences between
colectomised and non-colectomised patients suggest that pouches do not offer the same colonisation
conditions (even after years of surgery) as that the large intestine environment provides. Although
we did not find statistically significant differences between mature and immature UC pouch gut
microbiomes, our data suggest the dominance of Bacteroideaceae in mature pouches, which is in line
with the literature [10,24,25].
As mentioned above, responses to antibiotic therapy have a great significance in UC pouchitis
treatment. The logical question is whether patients who did not respond to antibiotic therapy have
an altered bacterial composition compared to antibiotic responders. The combination of antibiotics,
namely metronidazole and ciprofloxacin, can improve the outcome of the majority of pouchitis cases,
and only in 10–15% of cases does chronic, treatment refractory pouchitis develop [9]. This proportion
was comparable to our results. However, the long-term use of antibiotics may induce antibiotic
resistance [2]. An antibiotic course is associated with an overall reduction in bacterial richness [5,22].
In the study by Reshef et al. [10], samples from patients treated with chronic antibiotic therapy showed
lower diversity than samples from participants treated with immunomodulators or biologic therapies.
The decreased bacterial diversity that was seen in our Pouch cohort cannot only be explained by
high rates of antibiotic use among colectomised UC patients. The manipulation of gut microbiota
with probiotics and prebiotics is an obvious and practical strategy in the management of UC with
minimal adverse events. Some studies proved the induction of remission and prevention of relapse
with probiotics in the case of pouchitis, especially VSL#3, with mild to moderate disease activity.
On the other hand, the role of prebiotics is unclear [26,27].
Our study has some strengths and limitations. The first limitation is the relatively small number
of enrolled participants, although it corresponds with the literature in this topic. The second limitation
is that 16S RNA gene sequencing technique represents gene copy number, not true bacterial counts;
however, this methodology is currently the most widespread and used in investigations of gut bacterial
composition. The third limitation is that we did not examine the endoscopic and histological findings
of patients. Endoscopies were carried out only on a limited number of patients. Disease activity was
defined by clinical and laboratory parameters in order to avoid colonoscopy as an invasive intervention.
A strength of our study was the multi-group analysis: we compared data of multiform types of UC,
FAP and healthy participants, which allows for testing multiple relationships.
4. Materials and Methods
4.1. Patients
Active and inactive UC patients who underwent restorative proctocolectomy and IPAA formation
(“Pouch active and Pouch inactive”) and were treated at Department of Medicine, University of Szeged
were enrolled in the study. The enrollment period was between 31 January 2017 and 30 November 2018.
The sampling technique was consecutive sampling, therefore we enrolled every patient who met the
inclusion criteria during the enrollment period. For comparison, active and inactive UC patients with
different locations/extents treated at 1st Department of Medicine, University of Szeged, were also
enrolled (“UC active and UC inactive”). The other group of patients that was compared with the main
group (that is, UC patients with a pouch) was patients with FAP who underwent proctocolectomy
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and IPAA formation (“FAP”). The same number of healthy subjects were enrolled as a control group.
All of the patients and healthy volunteers who agreed to participate in the study signed an informed
consent form.
Clinical data of patients, blood and faecal samples were collected to determine C-reactive protein
(CRP), leukocyte and thrombocyte count, serum iron, haematocrit, haemoglobin, faecal calprotectin
concentration, and microbiota composition. Faecal samples were stored at −20 ◦C until processing.
Subjects’ serums were analysed after sampling. Patients were assessed depending on disease phenotype,
clinical activities and type of concomitant therapy. The response to drug treatment was also evaluated,
especially the response to antibiotic therapy in the case of UC patients with a pouch. Disease activity
was assessed by the clinical subscore of the Pouchitis Disease Activity Index (PDAI) [28] and clinical
subscore of the Mayo score (partial Mayo Score) [29].
4.2. Definitions
Inclusion criteria: Definitive UC for at least 3 months duration before enrolment, concomitant
treatments continued during the study period, such as 5-aminosalicylate and/or a corticosteroid, and/or
an immunosuppressant was permitted at a stable dose for at least 8 weeks prior to inclusion.
Exclusion criteria: age below 18 years, antibiotic or probiotic or gastric acid inhibitor use 6 weeks
before inclusion, steroid titration up to 6 weeks prior to study entry, chronic NSAID (nonsteroidal
anti-inflammatory drugs) use or NSAIDS within 6 weeks of study recruitment (apart from 5-ASA
therapy), pregnancy, any other inflammation of bowel than UC (for example diverticulitis or infectious
colitis), colon tumour, any acute or chronic severe disease especially bowel and autoimmune diseases,
active infection, ano-rectal cuff stricture, insufficiency of IPAA, fistulas, inability to give informed
consent and if the patient withdrew consent.
We defined the inflammation of the pouch (active) as ≥2 points in clinical subscore of the PDAI.
Remission (inactive) was defined as 0–1 subscore. In a case of UC, active disease was determined as
≥2 points of partial Mayo Score. Inactive disease was determined as 0–1 points of partial Mayo score.
Definition of “mature pouch”: time after ileostomy closure was more than 5 years. Immature
pouch: Time after ileostomy closure was less than 5 years.
4.3. Specimen Collection and Storage
Serum and faecal specimens for research were collected during enrolment time point. Serum was
analysed for CRP, complete blood count, serum albumin and iron level right after sampling. Following
defecation, stool samples were immediately placed into commercial 8 mL plastic tubes (Biolab®,
Budapest, Hungary) without buffer and tubes were transferred as soon as possible. If necessary, the
sample could be stored in the refrigerator until transport (±4 ◦C). Faecal samples were frozen within
4 h and stored at −20 ◦C until processing for the determination of calprotectin levels and microbiome
profiles. All frozen samples were processed within 6 months. One more stool specimen was sent for
microbiological tests to exclude infectious agents.
4.4. 16S rRNA-Based Bacterial Community Profiling
To determine the faecal microbiota composition for each individual involved in the study,
we sequenced and analysed the V4 hypervariable region of the 16S rRNA genes from faecal samples.
The metagenomic DNA was extracted from faecal samples by using ZR Fecal DNA MiniPrep™ kit
(Zymo Research, Irvine, CA, USA) following the manufacturer’s instructions. For DNA isolation, we
needed ≤ 150 mg faecal sample/individual. After donation, faecal samples were stored at −20 ◦C
until DNA isolation was performed. DNA concentration was determined for each sample using a
fluorometric method (Qubit dsDNA BR Assay Kit, Thermo Fischer Scientific, Waltham, MA, USA).
Extracted DNA was stored at −80 ◦C.
The V4 region of the 16S rRNA gene was PCR amplified with dual-indexed Illumina primer pairs,
using different combinations of barcoded forward and reverse primers (v4.SA501-508 and v4.SA701-707,
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respectively, Table S1) as previously described [30,31]. The primers consist of the appropriate Illumina
adapters, an 8 nt index sequence, a 10 nt pad sequence, a 2 nt linker and specific sites for the V4
region. The PCR reactions consisted of 1.5 µL (30 ng) of template DNA, 10 µL of Phusion HF buffer
(Thermo Fisher Scientific), 4 µL of 2.5 mM deoxynucleotide triphosphates mix (dNTPs), 0.5 µL of
Phusion DNA polymerase (2 U µL−1) (Thermo Fisher Scientific), 1–1 µL of primers, 10 µM each, 3 µL
DMSO (100%) and 29 µL of nuclease-free H2O in a final reaction volume of 50 µL. The following
thermocycler conditions were used: 95 ◦C for 2 min, 25 cycles of 95 ◦C for 20 s + 56 ◦C for 15 s + 72 ◦C
for 30 s and 72 ◦C for 10 min. Following gel electrophoreses of the PCR products, the 400 bp amplicons
were extracted from the gel (Thermo Fischer Scientific GeneJET Gel Extraction Kit) and, following a
second purification step (Zymo Research DNA Clean and Concentrator-5 Kit), were sequenced using
the MiSeq Illumina platform. To prepare the samples for sequencing, the amplicons were quantified
using a fluorometric method (Qubit dsDNA BR Assay Kit, Thermo Fischer Scientific) and libraries
were mixed with Illumina PhiX in a ratio of 0.95:0.05. Sequencing on the Illumina MiSeq instrument
was carried out with a v2 500 cycle sequencing kit (Illumina). Then, 100 µM stock custom sequencing
primers were mixed with standard read1, index read and read2 sequencing primers included in the
MiSeq cartridge.
After sequencing, 16S rRNA reads were demultiplexed and processed with the Mothur software
(version 1.42.0) There were 20,204 average counts per sample. To filter out the low read counts,
we followed the protocol of Rettedal, 2014 [32]. The number of sequences per sample was equalised to
3000 read counts using random re-sampling with a custom R script. Sequences were merged at the level
of 97% sequence identity and taxonomically assigned using the Silva ribosomal RNA database [33].
After removal of reads that could not be classified, 1689 OTUs remained.
To quantify within-group (e.g., Healthy group, FAP group) diversity from 16S rRNA data, we used
the vegan R package to calculate the most commonly used alpha diversity indices [34,35] (Fisher index,
Figure 1 and Figure S1; Shannon and inverse Simpson indices, Figure S2, Table S2). Unweighted
Unifrac distances (Figure 2 and Table S3) were computed with Phyloseq (version 1.22.3 R package) [36]
and pairvise permANOVA analysis was calculated with the pairwiseAdonis R package.
To identify differentially abundant taxa between different groups OTUs (operational taxonomic
unit) were classified at the family level because the V4 region allows accurate identification only
down to this level [37] (Table S4a). We applied edgeR (version 3.16.5 R package) [38] as suggested
previously [39]. To this end, abundances were normalised using the TMM (trimmed mean of M-values)
method [40] and then different groups were compared using negative binomial tests in a pairwise
manner. We used the Benjamini–Hochberg false discover rate correction method to correct the p values
for multiple testing [41] (Table S4b).
4.5. Ethics
Ethical approval was received from the Medical Research Council, Scientific and Research
Committee and the Regional and Institutional Human Medical Biological Research Ethics Committee,
University of Szeged (approval No.: 49/3-64/007; 42/2017-SZTE). All patients and volunteers were
informed of the study procedure. Their written informed consent was obtained.
4.6. Data analysis
To determine statistical differences between groups the following tests were used: Welch two
sample t-test, Wilcoxon rank sum test, pairwise permANOVA test and pairwise two-sided negative
binomial test. Statistical differences between groups for faecal calprotectin levels were determined
by the Mann–Whitney rank sum and Kruskal–Wallis one-way ANOVA on ranks test (normality test
failed). Descriptive parameters are shown as mean with standard deviation (SD); except for faecal
calprotectin was shown as median with minimum-maximum values. p-value < 0.05 was considered
as significant.
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5. Conclusions
The results of this study demonstrate a marked shift in gut microbiota in UC patients with
pouch. We verified significant difference in diversity between IBD and non-IBD groups, although
colectomised UC and FAP patients showed similar bacterial composition. In this line, gut microbiome
and its localisation together construct a functional unit that could be an explanation of our results.
More animal, transitional and clinical studies are needed with sophisticated molecular microbiologic
techniques to understand the complex networking and function of gut microbiome and its role in UC
with IPAA formation.
Supplementary Materials: The following are available online at http://www.mdpi.com/1424-8247/13/11/346/s1,
Figure S1: Alpha diversity differences between all groups. Data represent Fisher alpha diversity indices at the OTU
level based on 16S rRNA profiling of the V4 region. No significant difference was observed between Pouch_active
and Pouch_inactive, and UC_active and UC_inactive groups. Sample sizes were 6, 13, 9, 13, 7 and 8 for FAP,
Healthy, Pouch active, Pouch inactive, UC active and UC inactive groups, respectively. Central horizontal bars
represent median values. For details, see Table S2. Figure S2: Shannon (a) and inverse Simpson (b) alpha diversity
indices at the OTU level based on 16S rRNA profiling of the V4 region. Sample sizes were 6, 13, 9, 13, 7 and 8 for
FAP, Healthy, Pouch active, Pouch inactive, UC active and UC inactive groups, respectively. Central horizontal
bars represent median values. For details, see Table S2. Table S1: Primer sequences, Table S2: Diversity values
and Wilcoxon test results. Table S3: Pairwise permANOVA results. Table S4a: Bacterial abundance; Table S4b:
Differential abundance. Table S5: Patients all data final.
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